StemRIM Inc. announced that a medical use patent for the "Regeneration-Inducing MedicineTM" development candidate, Redasemtide, indicated for cardiomyopathy (dilated cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy), will soon be registered in Republic of the U.S. Title of Invention: Therapeutic agent for cardiomyopathy, old myocardial infarction, and chronic heart failure. Region.: The United States of America. Application No.

16/477,878. Registration No. To be determined.

Applicant. StemRIM Inc., Osaka University. This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy (Dilated cardiomyopathy, arechemic cardiomyopathy), and hypertensive cardiomyopath) in the U.S. To date, the company have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents.

The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.